Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.58%
0%
-10.58%
6 Months
-12.84%
0%
-12.84%
1 Year
-5.86%
0%
-5.86%
2 Years
2.08%
0%
2.08%
3 Years
15.06%
0%
15.06%
4 Years
-10.01%
0%
-10.01%
5 Years
9.5%
0%
9.5%
Recordati SpA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.61%
EBIT Growth (5y)
6.94%
EBIT to Interest (avg)
16.62
Debt to EBITDA (avg)
1.95
Net Debt to Equity (avg)
1.01
Sales to Capital Employed (avg)
0.58
Tax Ratio
24.13%
Dividend Payout Ratio
62.91%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
19.37%
ROE (avg)
25.39%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
5.79
EV to EBIT
19.40
EV to EBITDA
15.12
EV to Capital Employed
3.26
EV to Sales
5.21
PEG Ratio
2.92
Dividend Yield
20.45%
ROCE (Latest)
16.80%
ROE (Latest)
23.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
643.90
680.00
-5.31%
Operating Profit (PBDIT) excl Other Income
200.60
248.20
-19.18%
Interest
24.40
26.40
-7.58%
Exceptional Items
-15.70
-1.10
-1,327.27%
Consolidate Net Profit
91.10
125.00
-27.12%
Operating Profit Margin (Excl OI)
232.80%
290.10%
-5.73%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -5.31% vs 13.62% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -27.12% vs 60.05% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,341.60
2,082.30
12.45%
Operating Profit (PBDIT) excl Other Income
826.90
708.40
16.73%
Interest
81.20
74.50
8.99%
Exceptional Items
-22.40
-10.00
-124.00%
Consolidate Net Profit
416.50
389.20
7.01%
Operating Profit Margin (Excl OI)
281.80%
271.70%
1.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 12.45% vs 12.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 7.01% vs 24.62% in Dec 2023
About Recordati SpA 
Recordati SpA
Pharmaceuticals & Biotechnology
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Company Coordinates 
Company Details
Via M. Civitali, 1 , MILANO None : 20148
Registrar Details






